Manufacturer of Blinatumomab

The development and production of Blinatumomab (Blinatumomab) is completed by an American biopharmaceutical company called Amgen. Belintuzumab is a bispecific antibody and the first targeted immunotherapy drug for the treatment ofB cell malignancies. Its mechanism of action is novel and involves the in vivo binding of patient T cells to CD19-expressing tumor cells. Clinical trials have proven effective in relapsed B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma, including patients refractory to chemotherapy. Amgen has extensive experience and expertise in biopharmaceuticals and is committed to developing and launching innovative treatments to meet the needs of patients with serious diseases.